WO2003045415A3 - Self-assembling p53 peptides as gene delivery vehicles - Google Patents

Self-assembling p53 peptides as gene delivery vehicles Download PDF

Info

Publication number
WO2003045415A3
WO2003045415A3 PCT/CA2002/001783 CA0201783W WO03045415A3 WO 2003045415 A3 WO2003045415 A3 WO 2003045415A3 CA 0201783 W CA0201783 W CA 0201783W WO 03045415 A3 WO03045415 A3 WO 03045415A3
Authority
WO
WIPO (PCT)
Prior art keywords
self
delivery vehicles
peptides
assembling
gene delivery
Prior art date
Application number
PCT/CA2002/001783
Other languages
French (fr)
Other versions
WO2003045415A2 (en
Inventor
Jean Gariepy
Original Assignee
Univ Health Network
Jean Gariepy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network, Jean Gariepy filed Critical Univ Health Network
Priority to AU2002349204A priority Critical patent/AU2002349204A1/en
Publication of WO2003045415A2 publication Critical patent/WO2003045415A2/en
Publication of WO2003045415A3 publication Critical patent/WO2003045415A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Composite Materials (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Novel delivery vehicles comprising peptide based domains that can self-assemble into multivalent assemblies are described. The multivalent assemblies are preferably tetrameric assemblies such as hp53tet. The peptide domain is preferably fused to a signal molecule such as a polycationic molecule. The vehicles are useful in delivering a wide range of agents to a cell including peptides, vaccines, cytotoxic molecules, plasmids, genes, drugs and diagnostic probes or agents.
PCT/CA2002/001783 2001-11-26 2002-11-26 Self-assembling p53 peptides as gene delivery vehicles WO2003045415A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002349204A AU2002349204A1 (en) 2001-11-26 2002-11-26 Self-assembling p53 peptides as gene delivery vehicles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33250801P 2001-11-26 2001-11-26
US60/332,508 2001-11-26

Publications (2)

Publication Number Publication Date
WO2003045415A2 WO2003045415A2 (en) 2003-06-05
WO2003045415A3 true WO2003045415A3 (en) 2003-12-04

Family

ID=23298528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001783 WO2003045415A2 (en) 2001-11-26 2002-11-26 Self-assembling p53 peptides as gene delivery vehicles

Country Status (2)

Country Link
AU (1) AU2002349204A1 (en)
WO (1) WO2003045415A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071677A1 (en) * 2003-03-10 2007-03-29 Park Yoon J Non-toxic membrane-translocating peptides
EP2235043A2 (en) 2008-02-01 2010-10-06 Alpha-O Peptides AG Self-assembling peptide nanoparticles useful as vaccines
US8715678B2 (en) * 2008-07-25 2014-05-06 Syracuse University Method for inhibiting the formation of SET1 family core complexes
US20210353784A1 (en) * 2020-05-12 2021-11-18 Research Foundation Of The City University Of New York Detecting and treating cancers using cell penetrant mtp53-oligomerization-domain peptide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732348A1 (en) * 1995-03-31 1996-10-04 Rhone Poulenc Rorer Sa CONDITIONAL EXPRESSION SYSTEM
WO1996037621A2 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Für Proteinoptimierung Mbh Multimeric proteins
WO2000068384A2 (en) * 1999-05-12 2000-11-16 Xencor, Inc. NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS
WO2001071005A2 (en) * 2000-03-24 2001-09-27 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732348A1 (en) * 1995-03-31 1996-10-04 Rhone Poulenc Rorer Sa CONDITIONAL EXPRESSION SYSTEM
WO1996037621A2 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Für Proteinoptimierung Mbh Multimeric proteins
WO2000068384A2 (en) * 1999-05-12 2000-11-16 Xencor, Inc. NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS
WO2001071005A2 (en) * 2000-03-24 2001-09-27 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BROKX RICHARD D ET AL: "A stable human p53 heterotetramer based on constructive charge interactions within the tetramerization domain.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 4, 24 January 2003 (2003-01-24), pages 2327 - 2332, XP002253329, ISSN: 0021-9258 *
CHENE PATRICK: "The role of tetramerization in p53 function.", ONCOGENE, vol. 20, no. 21, 2001, pages 2611 - 2617, XP002253330, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
AU2002349204A8 (en) 2003-06-10
WO2003045415A2 (en) 2003-06-05
AU2002349204A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
Martin et al. Peptide-guided gene delivery
Tripathi et al. Cell penetrating peptides in preclinical and clinical cancer diagnosis and therapy
Vivès et al. Cell-penetrating and cell-targeting peptides in drug delivery
Behnam et al. Non-covalent functionalization of single-walled carbon nanotubes with modified polyethyleneimines for efficient gene delivery
ES2242453T3 (en) PEPTIDIC VECTORS OF SUBSTANCES THROUGH THE HEMATOENCEPHALIC BARRIER.
JP4320054B2 (en) Compositions and methods for polynucleotide delivery
Mahato Non-viral peptide-based approaches to gene delivery
Torchilin et al. Peptide and protein drug delivery to and into tumors: challenges and solutions
Gewirtz et al. Facilitating oligonucleotide delivery: helping antisense deliver on its promise.
Mintzer et al. Nonviral vectors for gene delivery
EP3381515B1 (en) Carrier complexes for delivering molecules to cells
US5972707A (en) Gene delivery system
Manickam et al. Influence of TAT-peptide polymerization on properties and transfection activity of TAT/DNA polyplexes
Zelphati et al. PNA-dependent gene chemistry: stable coupling of peptides and oligonucleotides to plasmid DNA
Chen et al. Peptide-based and polypeptide-based gene delivery systems
Yao et al. Strategies on the nuclear-targeted delivery of genes
Parhiz et al. From rationally designed polymeric and peptidic systems to sophisticated gene delivery nano-vectors
US20050163832A1 (en) Intracellular delivery of therapeutic agents
JP5093964B2 (en) Fibrin / fibrinogen conjugate
WO2003045415A3 (en) Self-assembling p53 peptides as gene delivery vehicles
Brokx et al. Peptide-and polymer-based gene delivery vehicles
Patel et al. A small, synthetic peptide for gene delivery via the serpin–enzyme complex receptor
Kichler et al. Receptor-mediated gene delivery with non-viral DNA carriers
US20040019188A1 (en) Targeting through integrins
Mudhakir et al. Topology of octaarginines (R8) or IRQ ligand on liposomes affects the contribution of macropinocytosis-and caveolae-mediated cellular uptake

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP